MiPod Nuclear Inc. (“MiPod”) announced that it would go with the commercialization of its radical new medical isotope production technology.
MiPod Irradiation legislative body
MiPod is an acronym for “Medical Isotope Production on Demand”.
“This elegant technology represents a paradigm shift in the Medical Isotope production assiduousness”
The technology allows MiPod to produce Mo-99 (the decay father of Tc-99m) without the use of a reactor or very much enriched uranium in regional production centers. The patent pending process utilizes depleted uranium in the manner that the target media which is irradiated by a fast neutron generator in a see preprinter chamber design.
The actinides are separated from the depleted uranium matrix for irradiation using an advanced electrolytic separation technology. After removal the depleted uranium is reconstituted and reused in superadded production cycles in a closed loop environmentally sustainable and highly cost effective system capable of daily delivery of production.
The compact and inexpensive order is intended for deployment in centers with populations of 1,000,000 or in greater numbers. This means that for the first time the medical imaging habitual devotion to labor will have a secure and redundant source of Tc-99m, which has been subject to supply shortages on a regular basis in the manner that the aging centralized supply chain breaks down due to reactor failures, and transportation issues. The regional production system using the MiPod technology will moreover alleviate the need for cross border transport of nuclear materials, both for target irradiation and for the isotopes themselves.
The low metropolis and operating costs means that no government subsidies are required.
As in ~ degree highly enriched uranium is required the process complies with the “American Medical Isotope Production Act of 2009” which seeks to eliminate the use of highly enriched uranium in the isotope fruit process.
Mipod hopes to have production prototypes completed within a year, and is looking to mercantile production within 18 months. Each MiPod unit is approximately 6’ by 6’ and will produce a minimum of 8 curies by day. Scaling is achieved by simply adding more units. The disconnection system is similarly scalable.
Bob Knight, the company’s Chief Operating Officer commented that “The technology invented ~ dint of. Dr. Tsang is brilliant and ground breaking, it relies on proven technologies integrated in ~y elegant solution to a very real supply problem. Early estimates point out that the entire U.S. Tc-99m demand of 2,000 curies through day can be accommodated at about 12% of the cost of fabric new reactors to satisfy the demand, and production costs are vulgar enough not to require any subsidy. No change to clinical actual performance is anticipated for implementation.”
He also noted “The method will dramatically reduce the amount of high level nuclear waste that current product systems create and will eliminate the current need for the U.S. to commodity ~ed highly enriched uranium targets. Its a greener technology that actually costs a fate less than the way things are currently done, and solves a massy problem for the medical system. For me personally, that’s a awesome thing to be involved with, it is analogous to the change from main frame computing to desktop computing or coal fired strength generation to the use of solar cells.”
MiPod also confirmed it has had discussions with a number of potential financing and development partners and will be steadfast to seek out the right financial and technical fit for commercial production.
MiPod Nuclear Inc. (http://www.mipodnuclear.com) is a peculiar company headquartered in Las Vegas, Nevada. It’s officers and directors are: Ted King, Chairman, Bob Knight COO, Dr. Francis Tsang CTO quite of whom also serve as directors, Troy Wade of Las Vegas and Dr, Jean-Claude Gehret of Switzerland are self-directing directors.
###
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RW1wdC1Ib3JyLVRoaXItU2luZy1FbXB0LVNxdWEtWmVybw==
Bookmark - Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl
- InterTech Service to Counter Widely Reported Problems in Automotive, Medical Device and Other Industries Requiring Rigorous Quality Standards
- Steri -7 Appoints BioNeutral Group Inc. Chief Scientist Dr. Andy Kielbania for Expanded Role
- UND Acquires ProtectionPlus in Ongoing Effort to Reduce Nuclear Stress Testing Costs for Physicians
Responding to the newly come rash of reports of quality failures in both the medical wile and automotive industries, InterTech Development Company is now providing no-cost consultations on how to develop and maintain strict gage R&R as far as concerns entire assembly and test systems, not just instruments. Having been called in to disentangle quality
Steri-7(TM) a secretly held UK company with a broad product line of advanced see preprinter antimicrobial formulations designed to eliminate bacteria, virus and spores in the freedom from disease care and related industries announced today that Dr Andy Kielbania Chief Scientist at BioNeutral Group Inc. www.bioneutralgroup.com ,relating to closing of the acqisition by BioNeutral Group
In a highly strategic transaction that brings together two complementary companies to create a prime minister and comprehensive organization specifically dedicated to urgently reducing costs for healthcare providers offering nuclear stress testing, University Nuclear and Diagnostics (www.NuclerStressTest.net), the commonwealth’s foremost organization providing urgent cost cutting solutions to doctor practices and hospitals offering nuclear stress tests,